Normal Cell Lineages and the Phenotype of the Breast Cancer Cell

  • Joyce Taylor-Papadimitriou
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

The importance of defining the malignant phenotype within the framework of the lineages of the normal cell from which it derives has been clearly demonstrated in the haemopoietic system where the subclassification of leukaemias achieved in this way has led to a more objective approach to disease management and therapy. The success of the approach has depended on 3 major factors, namely, 1) the availability of specific immunological markers (monoclonal antibodies) to define differentiation-related antigens, 2) the easy availability of circulating blood cells and 3) the development of culture systems where primitive and more differentiated progenitor cells could be cultured and induced to clonally differentiate.

Keywords

Hydrate Estrogen Adenocarcinoma Propa Electrophoresis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Taylor–Papadimitrou J and Gendler SJ: Molecular aspects of mucins. In: Hilgers J and Zotter S (eds) Cancer Reviews Vol. 11–12, Munksgaard, Copenhagen, Denmark 1988 pp 11–24Google Scholar
  2. 2.
    Gendler S, Taylor-Papadimitriou J, Burchell J and Duhig T: A polymorphic epithelial mucin expressed by breast and other carcinomas: Immunological and molecular studies. In: Human Tumor Antigens and Specific Tumor Therapy, UCLA Symposia on Molecular and Cellular Biology, New Series, Vol 99, Alan R Liss, Inc, New York 1989 pp 11–23Google Scholar
  3. 3.
    Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani E-N and Wilson D: Molecular cloning and expression of the human tumour-associated polymorphic epithelial mucin. J Biol Chem 1990 (265): 15286–15293PubMedGoogle Scholar
  4. 4.
    Lancaster CA, Peat N, Duhig T, Wilson D, Taylor-Papadimitiou J and Gendler SJ: Structure and expression of PEM: a gene conserving methylated CpGs in an expressed VNTR unit. Biochem Biophys Res Commun 1990 (173):1019–1029PubMedCrossRefGoogle Scholar
  5. 5.
    Wreschner DH, Hareuveni M, Tsarfaty I et al: Human epithelial tumor antigen cDNA sequences. Eur J Biochem 1990 (189):463–473PubMedCrossRefGoogle Scholar
  6. 6.
    Siddiqui J, Abe M, Hayes D, Shani E, Yunis E and Kufe D: Isolation and sequencing qf a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci USA 1990 (85):2320–2323CrossRefGoogle Scholar
  7. 7.
    Ligtenberg M, Vos H, Gennissen A and Hilkens J: Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 1990 (265):5573–5578PubMedGoogle Scholar
  8. 8.
    Swallow DM, Gendler S, Griffiths B, Corney G, Taylor-Papadimitriou J and Bramwell ME: The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature 1987 (328):82–84PubMedCrossRefGoogle Scholar
  9. 99.
    Girling A, Bartkova J, Burchell J, Gendler S, Gillett C and Taylor-Papadimitriou J: A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary darcinomas. Int J Cancer 1989 (43):1072–1076PubMedCrossRefGoogle Scholar
  10. 10.
    Hull SR, Bright A, Carraway KL, Abe M and Kufe D: Oligosaccharides of the DF3 antigen of the BT20 human breast carcinoma cell line. J Cell Biochem 1988 (Suppl 12E):130, AbstractGoogle Scholar
  11. 11.
    Hanisch F-G, Uhlenbruck G, Peter-Katalinic J, Egge H, Dabrowski J and Dabrowski U: Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyl-lactosamine backbones with Gal 3b(1–4) GlcNAc 3b(1–6) repeating units. J Biol Chem 1989(264):872–883PubMedGoogle Scholar
  12. 12.
    Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R and Lamport D: Development and characterisation of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987 (47):5476–5482PubMedGoogle Scholar
  13. 13.
    Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IFC, Bast RC, Jr and Finn OJ: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucinmolecule preferentially expressed by malignant cells. Cancer Res 1991 (51):2908–2916PubMedGoogle Scholar
  14. 14.
    Granowska M, Mather SJ, Jobling T, Naeem M, Burchell J, Taylor-Papadimitriou J, Shepherd J and Britton KE: Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours. Int J Biol Mark 1990 (5):89–96Google Scholar
  15. 15.
    Wilkinson MJS, Howell A, Harris M, Taylor-Papadimitriou J, Swindell R and Sellwood RA: The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer 1984 (33):299–304PubMedCrossRefGoogle Scholar
  16. 16.
    Nagle RB: Intermediate filaments: A review of the basic biology. Am J Surg Pathol 1988 (12):4–16PubMedGoogle Scholar
  17. 17.
    Moll R, Franke WW, Schiller DL, Geiger B and Krepler R: The catalog of human cytokeratins: patterns of expression of specific cytokeratins in normal epithelia, tumors and cultured cells. Cell 1982 (31):11–24PubMedCrossRefGoogle Scholar
  18. 18.
    Moll R, Schiller DLK and Franke WW: Identification of protein IT of the intestinal cytoskeleton as a novel Type I cytokeratin with unusual properties and expression patterns. J Cell Biol 1990 (111): 567–579PubMedCrossRefGoogle Scholar
  19. 19.
    Guelstein VI, Tchpysheva TA, Ermilova VD, Litvinova LV, Troyanovsky SM and Bannikov GA: Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int J Cancer 1988 (42): 147–153PubMedCrossRefGoogle Scholar
  20. 20.
    Taylor-Papadimitriou J, Wetzels R and Ramaekers F: Intermediate filament protein expression in normal and malignant human mammary epithelial cells. In: Dickson RB and Lippman ME (eds) Breast Cancer: Cellular and Molecular Biology III. Kluwer 1991 (in press)Google Scholar
  21. 21.
    Gould VE, Koukoulis GK, Jansson DS, Nagle RB, Franke WW and Moll R: Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast. Am J Pathol 1990 (137):1143–1155PubMedGoogle Scholar
  22. 22.
    Nagle RB, Boecker W, Davis JR, Heid HW, Kaufmann M, Lucas DO and Jarasch E-D: Characterisation of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986 (34):869–881PubMedCrossRefGoogle Scholar
  23. 23.
    Bartek J, Durban EM, Hallowes RC and Taylor-Papadimitriou J: A subclass of luminal epithelial cells in the human mammary gland, defined by antibodies to cytokeratins. J Cell Sci 1985 (75):17–33PubMedGoogle Scholar
  24. 24.
    Bartek J, Bartkova J and Taylor-Papadimitriou J: Keratin 19 expression in the adult and developing human mammary gland. Histochem J 1990 (22):537–544PubMedCrossRefGoogle Scholar
  25. 25.
    Bartek J, Taylor-Papadimitriou J, Miller N and Millis R: Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int J Cancer 1985 (36):299–306PubMedGoogle Scholar
  26. 26.
    Bartek J, Bartkova J, Schneider J, Taylor-Papadimitriou J, Kovarik J and Rejthar A: Expression of monoclonal antibody-defined epitopes of keratin 19 in human tumours and cultured cells. Eur J Cancer Clin Oncol 1986 (32):1441–1452CrossRefGoogle Scholar
  27. 27.
    Azumi N and Battifora H: The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. Am J Clin Pathol 1987 (88):286PubMedGoogle Scholar
  28. 28.
    Raymond WA and Leong A S-Y: Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J Pathol 1989 (157):299–306PubMedCrossRefGoogle Scholar
  29. 29.
    Cattoretti G, Andreola S, Clemente, C, D’Amato L and Rilke F: Vimentin and p53 expression in epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer 1988 (57):353–357PubMedCrossRefGoogle Scholar
  30. 30.
    Domagala W, Wozniak L, Lasota J, Weber K and Osborn M: Vimentin is preferentially expressed in high-grade ductal and medullary, but not in tabular breast carcinomas. Am J Pathol 1990 (137):1059–1064PubMedGoogle Scholar
  31. 31.
    Raymond WA and Leong ASY: Vimentin - A new prognostic parameter in breast carcinoma. J Pathol 1989(158):107–114PubMedCrossRefGoogle Scholar
  32. 32.
    Domagala W, Lasota J, Bartkowiak J, Weber K and Osborn M: Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 1990 (136):219–227PubMedGoogle Scholar
  33. 33.
    Domagala W, Lasota J, Dukowicz A, Markiewski M, Striker G, Weber K and Osborn M: Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol 1990 (137):1299–1304PubMedGoogle Scholar
  34. 34.
    Dairkee HS, Puett L and Hackett, AJ: Expression of basal and luminal epithelium-specific keratins in normal, benign and malignant breast tissue. JNCI 1988(80)1691–695Google Scholar
  35. 35.
    Wetzels RHW, Holland R, van Haelst UJGM, Lane EB, Leigh IM and Ramaekers FCS: Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carinomas of the breast. Am J Pathol 1990 (134):571–579Google Scholar
  36. 36.
    Dairkee SH, Mayall BH, Smith HS: Monoclonal marker that predicts early recurrence of breast cancer. Lancet 1987 (1):514–516PubMedGoogle Scholar
  37. 37.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Amplification of the her-2/neu oncogene correlates with relapse and survival in human cancer. Science 1987 (235):177–182PubMedCrossRefGoogle Scholar
  38. 38.
    van de Vijver, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, and Nusse R: Neu-protein overexpression in breast cancer. Association with the comedo type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988 (319):1239–1245PubMedCrossRefGoogle Scholar
  39. 39.
    Meissner K, Riviere A, Haupt G and Loning T: Study of Neu-protein expression in mammary Paget’s disease with and without underlying breast carcinoma and in extramammary Paget’s disease. Am J Pathol 1990 (137):1305–1309PubMedGoogle Scholar
  40. 40.
    Jacquemier JD, Hassoun J, Torrente M and Martin P-M: Districution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions in various stages – Immunohistochemical study of 107 cases. Breast Cancer Res and Treat 1990(15): 109–117CrossRefGoogle Scholar
  41. 41.
    Petersen OW, Hoyer PE and van Deurs B: Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 1987 (47): 5748–5751PubMedGoogle Scholar
  42. 42.
    Battersby S, Robertson BJ Anderson TJ, King RJB and McPherson K: Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptos in normal breast. 1991 (in press)Google Scholar
  43. 43.
    Perez R, Pascual M, Macias A and Lage A: Epidermal growth factor receptos in human breast cancer. Breast Cancer Res Treat 1984 (4): 189–193PubMedCrossRefGoogle Scholar
  44. 44.
    Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH and Schultz GS: Epidermal growth factor binding by breast-tumour biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res 1984 (44): 3448–3453PubMedGoogle Scholar
  45. 45.
    Sainsbury JRC, Farndon JJ, Sherbet GV and Harris AL: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1985 (i): 364–366CrossRefGoogle Scholar
  46. 46.
    Nicholson S, Sainsbury JRC, Halcrow P, Chambers P, Farndon JR and Harris AL: Expression of epidermal-growth-factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989 (i): 182–185CrossRefGoogle Scholar
  47. 47.
    Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987 (i): 1982–1987Google Scholar
  48. 48.
    Tsutsumi Y, Naber SP, deLellis RA, Wolfe HJ, Marks PJ, McKenzie SJ and Yin S: Neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. Hum Pathol 1990 (21): 750–758PubMedCrossRefGoogle Scholar
  49. 49.
    Stoker MGP, Pigott D and Taylor-Papadimitriou J: Response to epidermal growth factors of cultured human mammary epithelial cells from benign tumours. Nature 1976 (39): 279–282Google Scholar
  50. 50.
    Taylor-Papadimitriou J, Shearer M and Stoker MGP: Growth requirements of human mammary cells in culture. Int J Cancer 1977 (20):903–908PubMedCrossRefGoogle Scholar
  51. 51.
    Snedeker SM, Brown CF, DiAugstine RP: Expression and functional properties of transforming growth factor 3a and epidermal growth factor during mouse mammary gland ductal morphogenesis. Proc Natl Acad Sci USA 1991 (88): 276–280PubMedCrossRefGoogle Scholar
  52. 52.
    Valverius EM, Velu T, Shakar V, Ciardiello F, Kim N and Salomon DS: Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype. Int J Cancer 1990 (46): 712–718PubMedCrossRefGoogle Scholar
  53. 53.
    Stampfer M, Hallowes RC and Hackett AJ: Growth of normal human mammary cells in culture. In Vitro 1980 (16): 415–425PubMedCrossRefGoogle Scholar
  54. 54.
    Stampfer MR: Cholera toxin stimulation of human mammary epithelial cells in culture. In Vitro 1982 (18):531–537PubMedCrossRefGoogle Scholar
  55. 55.
    Buehring GC: Culture of human mammary epithelial cells: Keeping abreast of a new method. J Natl Cancer Inst 1972 (49): 1433–1434PubMedGoogle Scholar
  56. 56.
    Taylor-Papadimitrou J, Purkis P and Fentiman IS: Cholera toxia and analogues of cyclic AMP stimulate the growth of cultured mammary epithelial cells. J Cell Physiol 1980 (102): 317–321CrossRefGoogle Scholar
  57. 57.
    Taylor-Papadimitrou J, Stampfer M, Bartek J, Lewis A, Boshell M, Lane EB and Leigh IM: Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J Cell Science 1989 (94): 403–413Google Scholar
  58. 58.
    Hammond SL, Ham RG and Stmpfer MR: Serum-free growth of human mammary epithelial cells: Rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc Natl Acad Sci USA 1984 (81): 5435–5439PubMedCrossRefGoogle Scholar
  59. 59.
    Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valverius E, Clark R, McCormick F, Stampfer M, Abularach S and Gelmann EP: Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res 1989 (49):4258–4263PubMedGoogle Scholar
  60. 60.
    Curschellas E, Matter A and Regenass U: Immunolocalization of cytoskeletal elements in human mammary epithelial cells. Eur J Cancer Clin Oncol 1987 (23):1517–1527CrossRefGoogle Scholar
  61. 61.
    Ramaekers FCS, Haag D, Kant A, Moesker O, Jap PHK and Vooijs GP: Coexpression of keratin and vimentin-type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci USA 1983 (80):2618–2622PubMedCrossRefGoogle Scholar
  62. 62.
    Wolman SR, Smith HS, Stampfer M and Hackett AJ: Growth of diploid cells from breast cancers. Cancer Genet Cytogenet 1985 (16):49–64PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Joyce Taylor-Papadimitriou
    • 1
  1. 1.Imperial Cancer Research FundLondonUK

Personalised recommendations